Affiliation:
1. Department of Diabetes and Endocrinology Guy's and St. Thomas' NHS Foundation Trust London UK
2. Novo Nordisk A/S Søborg Denmark
Abstract
AbstractObjectiveThis study assessed the effects of semaglutide on body weight, cardiometabolic risk factors, and glycemic status in individuals categorized by baseline BMI with or without additional obesity‐related comorbidities, including prediabetes and high risk of cardiovascular disease (CVD).MethodsThis was a post hoc exploratory subgroup analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) 1 trial (NCT03548935), in which participants without diabetes and BMI ≥30 kg/m2, or BMI ≥27 kg/m2 with ≥1 weight‐related comorbidity, were randomized to once‐weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks. For this analysis, individuals were categorized into subgroups based on baseline BMI <35 versus ≥35 kg/m2 (with no additional criteria, with ≥1 comorbidity, with prediabetes, and with prediabetes and high risk of CVD).ResultsMean changes in body weight from baseline to week 68 with semaglutide were −16.2% and −14.0% in the subgroups with baseline BMI <35 and ≥35 kg/m2, respectively (both p < 0.0001 vs. placebo). Similar changes were observed in individuals with comorbidities, with prediabetes, and with prediabetes plus high CVD risk. The beneficial effects of semaglutide on cardiometabolic risk factors were consistent across all subgroups.ConclusionsThis subgroup analysis confirms that semaglutide is effective in individuals with baseline BMI <35 and ≥35 kg/m2, including in those with comorbidities.
Subject
Nutrition and Dietetics,Endocrinology,Endocrinology, Diabetes and Metabolism,Medicine (miscellaneous)
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献